Efficacy observation of bevacizumab combined with hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with malignant ascites / 肿瘤研究与临床

Objective:To evaluate the clinical effect of bevacizumab combined with hyperthermic intraperitoneal chemotherapy (HIPEC) on gastric cancer with malignant ascites.Methods:The data of 96 gastric cancer patients with malignant ascites in Tangshan People's Hospital in Hebei Province from August 2017 to December 2019 were retrospectively analyzed. The patients were divided into bevacizumab+HIPEC group (38 cases) and routine intraperitoneal chemotherapy group (58 cases). Both groups received oral chemotherapy with S-1. The serum tumor marker carcinoembryonic antigen (CEA) level, carbohydrate antigen 199 (CA199) level, objective response rate (ORR), disease control rate (DCR), quality of life (QOL) improvements, and occurrence of adverse reactions were compared between the two groups after they were treated for two courses.Results:Serum CEA and CA199 levels in the bevacizumab+HIPEC group were lower than those in the routine intraperitoneal chemotherapy group [(16±11) ng/ml vs. (24±14) ng/ml, (39±25) U/ml vs. (51±26) U/ml)], and the differences were statistically significant ( t = -2.962, P = 0.004; t = -2.361, P = 0.020). The ORR, DCR and improvement rate of QOL in the bevacizumab+HIPEC group were higher than those in the routine intraperitoneal chemotherapy group [63.2% (24/38) vs. 41.4% (24/58), 92.1% (35/38) vs. 75.9 % (44/58), and 78.9% (30/38) vs. 53.4% (31/58)], and the differences were statistically significant (all P < 0.05). The difference in the incidence of adverse reactions between the two groups was not statistically significant (all P > 0.05). Conclusion:Bevacizumab combined with HIPEC is a safe and effective approach for gastric cancer patients with malignant ascites.

Expression of BTG1 protein in laryngeal squamous cell carcinoma and its clinical significance / 临床耳鼻咽喉头颈外科杂志

OBJECTIVE@#To investigate the expression of B-cell translocation gene 1 (BTG1) and to determine the relationship between BTG1 expression and clinicopathological features, biological behaviors in laryngeal squamous cell carcinoma.@*METHOD@#Immunohistochemistry and Western blot were used to analyze BTG1 protein expression in 70 cases of laryngeal cancer and 35 cases of adjacent corresponding laryngeal mucosal tissues to illuminate the relationship between BTG1 expression and clinical factors.@*RESULT@#The positive rate of BTG1 protein expression was 31.43% in laryngeal carcinoma tissues, significantly lower than 91.43% in the adjacent laryngeal tissues (P 0.05) of patients with laryngeal cancer.@*CONCLUSION@#The expression of BTG1 protein was decreased in laryngeal squamous cell carcinoma, suggesting that BTG1 gene may be closely associated with the carcinogenesis and the degree of malignancy. Detection of BTG1 expression may be useful in diagnosis, treatment and prognosis of laryngeal carcinoma.

The effect of BTG1 overexpression on the proliferation and apoptosis of laryngeal cancer cells and its molecular mechanismin vitro / 中国癌症杂志

Background and purpose:B-cell translocation gene 1(BTG1) can inhibit cell proliferation, promote cell apoptosis and regulate cell cycle progression and differentiation in a variety of cell types. This study aimed to explore the inlfuence on cell proliferation, apoptosis and cell cycle and its related mechanism of laryngeal cancer Hep - 2 cell lines through BTG1 overexpression byin vitro experiments.Methods:The BTG1 expression plasmids were constructed and transfected into Hep-2. They were divided into experimental group (transfected BTG1 of Hep-2 cells) and control group (transfected empty plasmid of Hep-2 cells). Western blot method was used to identify BTG1 protein expression levels of cells; proliferation activity of cells was detected by MTT assay; lfow cytometry was used to analyze the cell cycle distribution and AnnexinⅤ-FITC/PI cell apoptosis; Western blot was also used to assay cell cycle regulatory protein and apoptosis-related protein expression.Results:The pEGFP-N1-BTG1 plasmid was constructed successfully, and the expression of BTG1 protein was higher in experimental group than that in control group (0.921±0.091vs 0.308±0.047,P<0.05). Compared with the two group of laryngeal cancer Hep-2 cells, the cell growth in experimental group was slowed down and the proliferation was reduced (P<0.05); Cyclin D1 protein expression level was decreased (0.436±0.023vs 0.916±0.092,P<0.05), the proportion of G0/G1 phase cell cycle was increased [(85.1±5.2)%vs (63.8±3.1)%,P<0.05], the proportion of S phase cell was decreased [(8.3±1.1)%vs (23.1±1.5)%, P<0.05], phosphatidylserine ectropion in experimental group was increased, cell early apoptosis was significant [(10.3±1.1)%vs (2.8±0.3)%,P<0.05] and anti-apoptotic protein Bcl-2 expression level was reduced(0.167±0.009vs 0.834±0.084,P<0.05).Conclusion:BTG1 high expression could inhibit the proliferation growth of laryngeal Hep-2 cells and promote its apoptosis, and the possible mechanisms are interrelated with BTG1 involved in cell cycle regulation and causing cell apoptosis.

Clinical study of oncoplastic breast-conserving surgery for the treatment of 30 cases of early breast cancer / 中国肿瘤临床

Objective:To evaluate the clinical effects of oncoplastic breast-conserving surgery on patients with early breast can-cer near the mammary areola. Methods:A total of 60 patients with early breast cancer underwent breast-conserving surgery in the Sec-ond Department of Breast Surgery, Tangshan People's Hospital from February 2011 to November 2013. These patients were random-ized into two groups, namely, the experimental Group A (n=30) and the control Group B (n=30). Oncoplastic breast-conserving surgery was performed on the patients in Group A, whereas Group B underwent standard breast-conserving surgery. The specimen weight of the locally excised breast, the nearest distance of the tumor to the surgical margins, and the postoperative cosmetic result of the affected breast were compared between the two groups. Results: The specimen weights of the locally excised breast were 71.03 ± 12.92 and 41.53±7.13 g, and the nearest distances of the tumor to the surgical margins were 13.30±2.97 and 10.63±1.65 mm in Groups A and B, respectively, with significant differences between the two groups (P0.05). Con-clusion:A larger amount of excised breast tissue and a wider scope of surgical margins were observed in Group A patients. However, the postoperative cosmetic result of the affected breast was almost similar for both groups. Therefore, oncoplastic breast-conserving sur-gery is a feasible and effective approach for early breast cancer patients.

Application of carbon nanoparticle-labeled lymph nodes in laparo-scopic curative resection for advancing rectal cancer / 中国肿瘤临床

Objective:To evaluate the clinical value of activated carbon nanoparticles for guiding lymphadenectomy in advanc-ing rectal cancer. Methods:Eighty rectal cancer patients who underwent laparoscopic curative resection for rectal cancer were divided into two groups:control group (40 cases) and experiment group (40 cases). The experiment group received carbon nanoparticle-labeled lymph nodes in surgery. The number of lymph nodes, lymph nodes≤5 mm in size, and positive lymph nodes, as well as the side effect of the procedure, were analyzed. Results:No complications were observed in the experiment group. The experiment group showed sig-nificantly higher values (P<0.05) than the control group for average number of lymph nodes (25.5 ± 8.78 vs. 16.05 ± 4.84), lymph nodes≤5mm in size (22.6 ± 8.25 vs. 13.65 ± 4.62), and positive lymph nodes (3.13 ± 4.14 vs. 1.35 ± 2.06). During operation, two dyed lymph nodes in two cases were found at the roof of the inferior mesenteric artery and along the side of the internal iliac artery. Dissec-tion was extended for these patients and the dyed lymph nodes were confirmed to be positive. Conclusion:Local injection of activated carbon nanoparticles around the tumor during surgical exploration was an effective, secure, and easy approach for guiding lymphade-nectomy in rectal cancer patients.